Eagle Total Other Income Expense Net vs Gross Profit Analysis
EGRX Stock | USD 3.73 0.08 2.10% |
Eagle Pharmaceuticals financial indicator trend analysis is much more than just examining Eagle Pharmaceuticals latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Eagle Pharmaceuticals is a good investment. Please check the relationship between Eagle Pharmaceuticals Total Other Income Expense Net and its Gross Profit accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eagle Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Eagle Stock please use our How to Invest in Eagle Pharmaceuticals guide.
Total Other Income Expense Net vs Gross Profit
Total Other Income Expense Net vs Gross Profit Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Eagle Pharmaceuticals Total Other Income Expense Net account and Gross Profit. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Eagle Pharmaceuticals' Total Other Income Expense Net and Gross Profit is 0.43. Overlapping area represents the amount of variation of Total Other Income Expense Net that can explain the historical movement of Gross Profit in the same time period over historical financial statements of Eagle Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Eagle Pharmaceuticals' Total Other Income Expense Net and Gross Profit is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Other Income Expense Net of Eagle Pharmaceuticals are associated (or correlated) with its Gross Profit. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Gross Profit has no effect on the direction of Total Other Income Expense Net i.e., Eagle Pharmaceuticals' Total Other Income Expense Net and Gross Profit go up and down completely randomly.
Correlation Coefficient | 0.43 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Total Other Income Expense Net
Gross Profit
Gross profit is a required income statement account that reflects total revenue of Eagle Pharmaceuticals minus its cost of goods sold. It is profit before Eagle Pharmaceuticals operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Most indicators from Eagle Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Eagle Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eagle Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Eagle Stock please use our How to Invest in Eagle Pharmaceuticals guide.At this time, Eagle Pharmaceuticals' Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 31.1 M in 2024, whereas Sales General And Administrative To Revenue is likely to drop 0.25 in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 1.6M | 4.0M | 4.7M | 4.9M | Depreciation And Amortization | 3.8M | 12.0M | 13.8M | 14.5M |
Eagle Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Eagle Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Eagle Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 254.6M | 253.2M | 253.7M | 406.2M | 467.1M | 490.4M | |
Short Long Term Debt Total | 38.6M | 37.1M | 25.6M | 62.5M | 71.8M | 41.6M | |
Other Current Liab | 2.3M | 3.1M | 7.0M | 85.8M | 98.7M | 103.7M | |
Total Current Liabilities | 38.8M | 38.1M | 74.4M | 111.1M | 127.8M | 134.1M | |
Total Stockholder Equity | 179.2M | 186.0M | 176.5M | 233.6M | 268.6M | 138.0M | |
Property Plant And Equipment Net | 2.2M | 2.1M | 1.6M | 1.2M | 1.3M | 2.3M | |
Current Deferred Revenue | 21.7M | 26.1M | 20.7M | 25.4M | 29.2M | 17.3M | |
Net Debt | (71.2M) | (66.1M) | (72.1M) | 7.1M | 6.4M | 6.8M | |
Retained Earnings | 72.5M | 84.5M | 75.9M | 111.5M | 128.2M | 134.6M | |
Accounts Payable | 5.5M | 6.3M | 16.4M | 19.0M | 21.8M | 22.9M | |
Cash | 109.8M | 103.2M | 97.7M | 55.3M | 63.6M | 73.0M | |
Non Current Assets Total | 75.1M | 87.1M | 81.1M | 217.4M | 250.0M | 262.5M | |
Non Currrent Assets Other | 3.9M | 5.0M | 4.2M | 15.7M | 18.1M | 19.0M | |
Other Assets | 13.9M | 32.4M | 29.1M | 52.9M | 60.8M | 63.9M | |
Long Term Debt | 38.2M | 33.6M | 25.1M | 56.2M | 64.6M | 67.9M | |
Cash And Short Term Investments | 109.8M | 103.2M | 97.7M | 55.3M | 63.6M | 75.1M | |
Net Receivables | 48.0M | 51.1M | 41.1M | 72.4M | 83.3M | 87.5M | |
Common Stock Shares Outstanding | 14.1M | 13.8M | 13.1M | 13.1M | 15.0M | 14.9M | |
Liabilities And Stockholders Equity | 254.6M | 253.2M | 253.7M | 406.2M | 467.1M | 490.4M | |
Non Current Liabilities Total | 36.6M | 29.1M | 2.9M | 61.5M | 70.7M | 74.3M | |
Inventory | 6.6M | 8.1M | 21.9M | 47.8M | 55.0M | 57.7M | |
Other Current Assets | 15.1M | 1.6M | 11.9M | 13.2M | 15.2M | 8.2M | |
Other Stockholder Equity | 106.7M | 101.5M | 100.7M | 123.2M | 110.8M | 100.8M | |
Total Liab | 75.4M | 67.2M | 77.3M | 172.6M | 198.5M | 208.4M | |
Property Plant And Equipment Gross | 2.2M | 2.1M | 7.6M | 7.8M | 8.9M | 9.4M | |
Total Current Assets | 179.4M | 166.1M | 172.6M | 188.8M | 217.1M | 137.0M | |
Short Term Debt | 6.3M | 5M | 8M | 25.6M | 7.2M | 8.5M | |
Property Plant Equipment | 2.2M | 2.1M | 1.6M | 1.2M | 1.3M | 2.3M | |
Net Tangible Assets | 123.8M | 133.4M | 126.0M | 70.2M | 80.7M | 106.8M | |
Retained Earnings Total Equity | 72.5M | 84.5M | 75.9M | 111.5M | 128.2M | 134.6M | |
Capital Surpluse | 278.5M | 305.4M | 325.8M | 366.3M | 421.2M | 282.9M | |
Treasury Stock | (171.9M) | (203.9M) | (225.1M) | (243.1M) | (218.8M) | (207.9M) | |
Intangible Assets | 15.6M | 12.9M | 10.7M | 118.3M | 136.1M | 142.9M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.MSFT | Microsoft | |
GM | General Motors | |
CRM | Salesforce |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eagle Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Eagle Stock please use our How to Invest in Eagle Pharmaceuticals guide.You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Complementary Tools for Eagle Stock analysis
When running Eagle Pharmaceuticals' price analysis, check to measure Eagle Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eagle Pharmaceuticals is operating at the current time. Most of Eagle Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eagle Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eagle Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eagle Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Stocks Directory Find actively traded stocks across global markets | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing |
Is Eagle Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eagle Pharmaceuticals. If investors know Eagle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eagle Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.87) | Earnings Share 0.85 | Revenue Per Share 19.684 | Quarterly Revenue Growth (0.13) | Return On Assets 0.0663 |
The market value of Eagle Pharmaceuticals is measured differently than its book value, which is the value of Eagle that is recorded on the company's balance sheet. Investors also form their own opinion of Eagle Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eagle Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eagle Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eagle Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eagle Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eagle Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eagle Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.